Integra Lifesciences Holdings (IART) Revenue (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Revenue data on file, last reported at $391.9 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 2.42% year-over-year to $391.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (up 1.24% YoY), and the FY2025 full-year result was $1.6 billion, up 1.53% from the prior year.
• Revenue fell to $391.9 million in Q1 2026, from $434.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $442.6 million in Q4 2024 to a low of $368.9 million in Q1 2024.
• A 5-year average of $396.3 million and a median of $391.9 million in 2026 frame the typical range for Revenue.
• Across the five-year window, Revenue slipped 4.16% in 2023 and advanced 11.49% in 2024, its largest moves.
• Tracing IART's Revenue over 5 years: stood at $398.0 million in 2022, then dropped by 0.25% to $397.0 million in 2023, then increased by 11.49% to $442.6 million in 2024, then slipped by 1.74% to $434.9 million in 2025, then fell by 9.89% to $391.9 million in 2026.
• Business Quant data shows IART's Revenue at $391.9 million in Q1 2026, $434.9 million in Q4 2025, and $402.1 million in Q3 2025.